Tyring, S., Belanger, R., Bezwoda, W., Ljungman, P., Boon, R. and Saltzman, R.L. (2001) A Randomized, Double-Blind Trial of Famciclovir versus Acyclovir for the Treatment of Localized Dermatomal Herpes Zoster in Immunocompromised Patients. Cancer Investigation, 19, 13-22.
https://doi.org/10.1081/CNV-100000070

has been cited by the following article:

• TITLE: Clinical Study: Lotion Containing Propolis Special Extract GH 2002 0.5% vs. Placebo as On-Top Treatment of Herpes Zoster

  AUTHORS: Denisa Tomanova, Simona Holcova, M. Hladíková

  KEYWORDS: Herpes Zoster, Propolis, Controlled Clinical Trial

  JOURNAL NAME: Health, Vol.9 No.10, September 22, 2017

  ABSTRACT: Background: The aim of the clinical trial was to establish the contribution of propolis special extract GH 2002 as constituent of a lotion for the supportive treatment of Herpes zoster. Methods: 60 patients with diagnosed Herpes zoster were either treated with a propolis containing (n = 33) or an identical, but propolis-free lotion (n = 27) for 28 days, as an add-on therapy to oral antiviral treatment with aciclovir. Study parameters were the assessment of pain on a visual analogue scale, the assessment of the formation of new vesicles, and the safety of application of the preparation. Results: Improvement of pain was significantly better and quicker in the propolis lotion group (p